7 results match your criteria: "Japan Animal Specialty Medical Institute Inc.[Affiliation]"
Temporal changes in clinical and radiographic variables in dogs with preclinical myxomatous mitral valve disease: The EPIC study.
J Vet Intern Med
May 2020
Boehringer Ingelheim, Animal Health, Ingelheim am Rhein, Germany.
Article Synopsis
- The EPIC study monitored dogs with myxomatous mitral valve disease (MMVD) to observe how they develop congestive heart failure (CHF).
- It compared clinical and radiographic changes in dogs that developed CHF against those that did not, analyzing factors like heart rate and respiratory rate.
- Key findings showed that dogs approaching CHF had significant increases in respiratory rates and heart rates, along with decreases in body weight and temperature, highlighting respiratory rates as crucial indicators of CHF onset.
Longitudinal Analysis of Quality of Life, Clinical, Radiographic, Echocardiographic, and Laboratory Variables in Dogs with Preclinical Myxomatous Mitral Valve Disease Receiving Pimobendan or Placebo: The EPIC Study.
J Vet Intern Med
January 2018
Animal Health, Boehringer Ingelheim, Ingelheim am Rhein, Germany.
Background: Changes in clinical variables associated with the administration of pimobendan to dogs with preclinical myxomatous mitral valve disease (MMVD) and cardiomegaly have not been described.
Objectives: To investigate the effect of pimobendan on clinical variables and the relationship between a change in heart size and the time to congestive heart failure (CHF) or cardiac-related death (CRD) in dogs with MMVD and cardiomegaly. To determine whether pimobendan-treated dogs differ from dogs receiving placebo at onset of CHF.
Effect of Pimobendan in Dogs with Preclinical Myxomatous Mitral Valve Disease and Cardiomegaly: The EPIC Study-A Randomized Clinical Trial.
J Vet Intern Med
November 2016
Boehringer Ingelheim, Animal Health, Ingelheim am Rhein, Germany.
Background: Pimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD). Its effect on dogs before the onset of CHF is unknown.
Hypothesis/objectives: Administration of pimobendan (0.
Efficacy of pimobendan on survival and reoccurrence of pulmonary edema in canine congestive heart failure.
J Vet Med Sci
January 2017
Japan Animal Specialty Medical Institute Inc., JASMINE Veterinary Cardiovascular Medical Center, 2-7-3 Nakagawa, Tsuzuki, Yokohama, Kanagawa 224-0001, Japan.
The aim of this study was to evaluate the efficacy of pimobendan with conventional therapies on survival and reocurrence of pulmonary edema in dogs with congestive heart failure (CHF) caused by myxomatous mitral valve disease (MMVD). Records of 197 client-owned dogs from 14 veterinary hospitals were included in this study. Dogs were administered conventional treatments with or without pimobendan.
View Article and Find Full Text PDFPlasma cytokine levels in dogs undergoing cardiopulmonary bypass.
Res Vet Sci
August 2015
JASMINE Veterinary Cardiovascular Medical Center, Japan Animal Specialty Medical Institute Inc., 2-7-3 Nakagawa, Tsuzuki, Yokohama, Kanagawa 224-0001, Japan. Electronic address:
Unlabelled: Currently, there are no reports of inflammatory responses to CPB in dogs. We investigated the time course of pro- and anti-inflammatory cytokine levels during and after CPB.
Animals: The study group included 11 dogs that underwent mitral valve repair with CPB, and the control group included 7 healthy dogs that underwent ovariohysterectomy.
Pathologic Manifestations on Surgical Biopsy and Their Correlation with Clinical Indices in Dogs with Degenerative Mitral Valve Disease.
J Vet Intern Med
June 2016
Veterinary Cardiovascular Medicine and Surgery Unit, Department of Veterinary Medicine, College of Bioresource Sciences, Nihon University, Fujisawa, Kanagawa, Japan.
Background: Evaluation of myocardial function is clinically challenging in dogs with degenerative mitral valve disease (DMVD). Although myocardial dysfunction is caused by pathologic degeneration, histopathologic progression is poorly understood.
Objectives: To characterize myocardial and pulmonary pathologic changes according to severity in dogs with naturally occurring DMVD, and to investigate whether or not pathologic degeneration is reflected by traditional clinical indices.
Successful implantation of autologous valved conduits with self-expanding stent (stent-biovalve) within the pulmonary artery in beagle dogs.
J Vet Cardiol
March 2015
Division of Medical Engineering and Materials, National Cerebral and Cardiovascular Center Research Institute, 5-7-1 Fujishiro-dai, Suita, Osaka 565-8565, Japan; Japan Animal Specialty Medical Institute Inc., 2-7-3, Nakagawa, Tsuduki-ku, Yokohama, Kanagawa 224-0001, Japan. Electronic address:
Objectives: To evaluate the functionality of an autologous heart valve with stent (Stent-biovalve or SBV) after implantation in the pulmonic valve position in beagle dogs.
Animals: Five beagle dogs.
Methods: A mold with an aperture of a tri-leaflet structure was constructed from a pair of concave and convex rods to which a nitinol (NiTi) stent was mounted.